# 1. Financial Performance ## A. Key Figures * **Consolidated Income:** ₹162 Cr Q2 (+61% YoY, +17% QoQ) · ₹300 Cr H1 (+66% YoY) * **EBITDA:** ₹50 Cr Q2 (+113% YoY) · ₹84 Cr H1 (+88% YoY) * **PAT:** ₹30 Cr Q2 (+131% YoY) · ₹51 Cr H1 (+114% YoY) * **Cash Flow from Operations:** ₹31 Cr H1 (vs. ₹9 Cr prior year) · ₹11 Cr in Q2 * **EBITDA Margin:** 31% Q2 (+750 bps YoY, +580 bps QoQ) * **H1 EBITDA-to-CFO Ratio:** 38% (Q2: 40%) ## B. Revenue Growth * **Robust Top-Line Momentum:** Revenue growth fueled by successful new product launches in regulated markets, with a broadening, more predictable product mix. * **Sustainable Revenue Streams:** Profit share and licensing fees now form a **major and stable component** of income, reducing reliance on one-off spikes. * **Out-Licensing Contribution:** Out-licensing income in the quarter reached **₹12 Cr**, underscoring IP monetization strength. ## C. Profitability Trends * **Margin Expansion Accelerates:** EBITDA margin surged to 31% in Q2, reflecting operating leverage and disciplined cost management despite rising employee costs. * **Gross Margin Trajectory:** Current gross margin near **55%**, with a clear path to **60–65%** as API integration advances. * **D. S. Segment Profitability:** Consolidated U.S. business (Havix + Senores Inc.) delivers best-in-class **40–42% EBITDA margins**, highlighting value of integrated manufacturing and IP. * **Cost Outlook:** Employee expenses expected to stabilize at **₹27–28 Cr per quarter**, supporting margin predictability. ## D. Balance Sheet * **Working Capital Discipline:** Trade receivables increased but remain within manageable days; working capital cycle expected to hold at **90–100 days**, with H2 pressure from emerging markets. ## E. Cash Flow * **Cash Flow Conversion Strengthens:** H1 operating cash flow tripled YoY, with EBITDA-to-CFO ratio improving to **38% (Q2: 40%)**, signaling enhanced capital efficiency. * **Liquidity & Return Outlook:** Management expects further improvement in cash flow metrics as scale increases, boosting liquidity and return potential. * **OCI Impact:** **₹8 Cr** loss in Other Comprehensive Income due to foreign currency translation adjustments on share transfers. --- # 2. Product & Segment Performance ## A. Key Figures * **Regulated Markets Revenue:** ₹107 Cr Q2 (+87% YoY, +19% QoQ) · ₹197 Cr H1 (+78% YoY) * **Emerging Markets Revenue:** ₹32 Cr Q2 (+9% QoQ) · ₹61 Cr H1 (+4% YoY) * **Branded Generics Revenue:** ₹12 Cr Q2 (10x YoY) · ₹20 Cr H1 (7x YoY) ## B. Regulated Markets * **Dominant Growth Engine:** Regulated markets, the largest vertical, delivered robust double-digit growth driven by portfolio expansion, proprietary product launches, and strong customer acquisition. * **Margin Expansion:** EBITDA margins improved significantly to **44% in Q2**, reflecting successful in-house ANDA filings and government channel controlled substance launches. * **Own Products Momentum:** Company-owned products in regulated markets grew by **over 60%**, with a profit-share model enhancing profitability and cash flow. * **Revenue Mix Stability:** Regulated segment expected to maintain ~65% of total revenue, with CDMO-CMO contributing ~$12 Mn in visible business and balanced mix between own and contract products. * **Strategic Focus:** Capital allocation and growth initiatives remain centered on regulated markets, underpinned by high pipeline visibility and execution capability. ## C. Emerging Markets * **Operational Recovery:** Emerging markets showed sequential improvement in revenue and profitability, turning cashflow positive despite geopolitical headwinds and dollar volatility. * **Commercialization Delays:** Despite 80+ product registrations, growth constrained by import permit bottlenecks and delayed order conversion, limiting YoY momentum. * **Margin Upside Ahead:** Margins expected to reach **early double-digits by year-end**, supported by niche molecule focus and improved pricing, boosting blended EBITDA. * **Diversification Playbook:** Strategic push into emerging markets with 1,000+ registrations aims to de-risk geographic concentration and leverage long-term growth in high-potential regions. ## D. Branded Generics * **Explosive Growth Trajectory:** India’s branded generics business achieved over 7-fold H1 revenue growth, with PAN-India rollout and hospital channel penetration accelerating scale. * **Scalable Margin Profile:** EBITDA margins at **18–20%** with expansion expected as reach and portfolio grow; business generates positive cash flow from inception. * **Pipeline & Capacity:** CDMO-CMO portfolio expanded to ~32 products with **50+ in pipeline**, supported by U.S.-based manufacturing for supply chain agility. * **Strategic Partnerships:** Zoraya’s U.S. marketing infrastructure and Senores Inc.’s IP holdings derisk and accelerate CGT and generic product launches. * **Revenue Outlook:** Branded generics on track for ~₹50 Cr in FY26, with target to double to **₹100 Cr+ next year** through new divisions and expanded footprint. --- # 3. Product Portfolio & Launches ## A. Key Figures * **New Product Launches:** **8** in Q2 FY'26 * **Regulated Market Portfolio:** **81** products * **Products Under Registration:** **824** in emerging markets * **Registered Products:** **394** as of Sep-30, 2025 ## B. New Product Launches * **Accelerated Innovation:** Robust new product cadence with **8 launches in Q2**, including from the acquired ANDA portfolio, enhancing basket diversification and growth runway. * **Zoraya Platform Rollout:** Strategic branded platform launched to commercialize key acquired products under company label, signaling enhanced control over positioning and pricing. * **Sustained Launch Momentum:** Management targets **quarterly product launches over the next 4–5 quarters**, focused on regulated markets, with potential tailwinds for margin performance. * **Semaglutide Progress:** Tablet dossier filed in **12–14 ROW markets**; injectable version under filing in multiple emerging markets, unlocking a **significant growth opportunity** despite lack of third-party market data. ## C. ANDA Pipeline * **Deep Regulated Pipeline:** **Close to 70 products in development**, with **8–10 ANDAs planned for H1 FY'27** and **6–8 in second half of current year**, reinforcing visibility into future launches. ## D. Registration Progress * **Strong Regulatory Throughput:** **86 new product approvals in the quarter** reflect improved agency engagement and pipeline velocity in emerging markets. --- # 4. Manufacturing & Capacity ## A. Key Figures * U.S. Capacity: 2 billion units post-expansion (+67% from 1.2B) **B. S. Capacity:** **200 Cr units** post-expansion (+67% from 120 Cr) * **Ratnatris Revenue:** **₹55–56 Cr** at acquisition · **₹150 Cr** projected by FY'25 (+~3x) * **Product Registrations (Ratnatris):** **47–48** at acquisition · **394** by FY'25 (+6x) * **Per-Unit Realization (Ratnatris):** **₹2** pre-CFY · **₹8–9** currently (+300%) * **New API Facility Revenue (Year 1):** **₹50–100 Cr** targeted ## B. U.S. Facility Expansion * **Strategic Capacity Buildout:** U.S. manufacturing footprint set to double with two new lines—third line in Q3 FY'26, fourth by end-FY'26—providing ample headroom for growth. * **Sterile Capability On Horizon:** First sterile facility in the U.S. targeting launch in Q2/Q3 FY'27, enabling entry into **general injectables and biologic CDMO-CMO** markets. * **Greenfield Execution Track Record:** Havix, a fully built-from-scratch facility, achieved commercial launch in 2019 post-inspection, demonstrating proven execution capability. * **Integration Challenges Persist:** Ratnatris and Havix synergies remain delayed, with concerns over **continued siloing of U.S. manufacturing and India R&D teams** as separate cost centers. ## C. API Integration * **Backward Integration Accelerating:** First API facility targeting US FDA approval in Q2 FY'26–FY'27; second facility to commence production post-approval, enhancing supply chain control. * **Margin Expansion Pathway:** Management guides to a **sustainable gross margin of 60–65%**, supported by in-house API integration, though full impact not quantifiable before FY'27–FY'28. --- # 5. Supply Chain & Vertical Integration ## A. API Sourcing Strategy * **Cost-Driven Make-or-Buy Approach:** API sourcing decisions will prioritize economic efficiency, with external procurement retained where it outperforms captive production. * **Strategic Self-Sufficiency Push:** Plans to bring **certain API production in-house within 1–2 years** to secure supply chain continuity for critical formulations. ## B. Backward Integration * **Macro-Integration Underway:** A comprehensive backward integration strategy is being executed, anchored by an **API facility with over 100 metric tons annual capacity**. * **Regulated Markets in Focus:** API investments are largely complete, with ongoing prioritization in regulated markets and only incremental spend for mid-tier standardized markets. --- # 6. Risks & Regulatory Exposure ## A. Geopolitical & Execution Risks * **Past Disruptions Contained:** Havix operations faced significant setbacks during 2020–2021 due to pandemic-related lockdowns, delaying integration and performance expectations. * **Limited Competitive Replication:** Despite apparent viability, few peers have successfully replicated the model—potential execution slippage or mid-cycle dropouts may be inhibiting adoption. * **No Materialized Threats:** Key strategic risks remain unmanifested; leadership emphasizes that current opportunities are below thresholds where exclusivity expiry would trigger immediate, large-scale competition. ## B. Supply Chain Resilience * **Low China Exposure:** Only **one API** is currently sourced from China, significantly reducing vulnerability to tariffs and regional supply shocks. * **De-risking Regulated Supply Chains:** In markets like the US, certain products depend on single-source API suppliers, but internal API capacity is under development to reduce long-term dependency. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **25%–30%** sustainable CAGR post-FY'26 (ex-cl. sterile facilities) * **Gross Margin Guidance:** **60%–65%** * **EBITDA Margin Outlook:** **28%–30%** sustainable from next year; **40%–45%** for combined US entity * **Regulated Markets Contribution:** **>40%** of total business * **Regulated Markets Margins:** **40%–42%** (expected stabilization) ## B. Revenue Targets * **Double-Digit Momentum:** Emerging markets on track for double-digit growth in FY'26–FY'27, with current-year growth reaffirmed. * **Long-Term Scaling Ambition:** Management targets **at least 30% CAGR over 3–5 years**, driven by product launches, though characterized as internal aspiration. * **CDMO-CMO Strength:** Business has seen multi-fold year-on-year expansion, with trajectory supporting **>30% CAGR** in coming years. * **Sterile Facility Exclusion:** Current growth guidance does not factor in future contributions from sterile operations, which remain in early planning. ## C. Margin Expectations * **Profitability Framework:** Company expects to sustain **overall profitability margins of 40%–42%**, supported by high-margin regulated segments. * **EBITDA Resilience:** Margins expected to remain stable from next year onward, with **like-to-like PAT margin expansion of a few hundred bps** anticipated due to low leverage. * **US Entity Premium:** Combined US operations projected to maintain **40%–45% EBITDA margins**, significantly above legacy Ratnatris levels. * **Seasonal Trend Continuity:** H2 typically outperforms H1; no lumpiness expected, supporting margin consistency.